TRACON Pharmaceuticals, Inc. (TCON)
OTCMKTS
· Delayed Price · Currency is USD
0.0632
+0.0052 (8.97%)
Nov 14, 2024, 2:47 PM EST
TRACON Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 3.2 | 12.05 | - | 0.35 | - | - | Upgrade
|
| Revenue Growth (YoY) | -64.44% | - | - | - | - | - | Upgrade
|
| Cost of Revenue | 12.11 | 12.28 | 13.89 | 11.15 | 8.2 | 14.53 | Upgrade
|
| Gross Profit | -8.91 | -0.23 | -13.89 | -10.8 | -8.2 | -14.53 | Upgrade
|
| Selling, General & Admin | 5.46 | 6.67 | 14.01 | 17.55 | 8.03 | 7.77 | Upgrade
|
| Research & Development | -5.06 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 0.4 | 6.67 | 14.01 | 17.55 | 8.03 | 7.77 | Upgrade
|
| Operating Income | -9.31 | -6.9 | -27.89 | -28.35 | -16.22 | -22.3 | Upgrade
|
| Interest Expense | -0.61 | -7.3 | -0.99 | -0.32 | -0.55 | -0.39 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.02 | -0.01 | -0.25 | -0 | -0.01 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -9.81 | -14.21 | -29.14 | -28.67 | -16.78 | -22.67 | Upgrade
|
| Other Unusual Items | 15 | 10.63 | - | - | - | - | Upgrade
|
| Pretax Income | 5.2 | -3.59 | -29.14 | -28.67 | -16.78 | -22.67 | Upgrade
|
| Net Income | 5.2 | -3.59 | -29.14 | -28.67 | -16.78 | -22.67 | Upgrade
|
| Net Income to Common | 5.2 | -3.59 | -29.14 | -28.67 | -16.78 | -22.67 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 80.20% | 56.53% | 21.25% | 92.03% | 196.09% | 12.61% | Upgrade
|
| EPS (Basic) | 2.29 | -2.19 | -27.85 | -33.23 | -37.34 | -149.45 | Upgrade
|
| EPS (Diluted) | 2.27 | -2.20 | -27.85 | -33.23 | -37.40 | -149.45 | Upgrade
|
| Free Cash Flow | 9.22 | 3.68 | -26.26 | -22.62 | -17.05 | -23.65 | Upgrade
|
| Free Cash Flow Per Share | 4.06 | 2.25 | -25.10 | -26.22 | -37.95 | -155.88 | Upgrade
|
| Gross Margin | -278.31% | -1.93% | - | - | - | - | Upgrade
|
| Operating Margin | -290.78% | -57.27% | - | -8192.77% | - | - | Upgrade
|
| Profit Margin | 162.34% | -29.79% | - | -8285.26% | - | - | Upgrade
|
| Free Cash Flow Margin | 288.06% | 30.52% | - | -6537.28% | - | - | Upgrade
|
| EBITDA | -9.29 | -6.88 | -27.88 | -28.33 | -16.21 | -22.27 | Upgrade
|
| EBITDA Margin | -290.34% | -57.15% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | Upgrade
|
| EBIT | -9.31 | -6.9 | -27.89 | -28.35 | -16.22 | -22.3 | Upgrade
|
| EBIT Margin | -290.78% | -57.27% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.